Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Icotrokinra→

Icotrokinra PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2763602-16-8
Molecular formula
C90H120N20O22S2
Molecular weight
1898.19 g/mol
Drug class
Interleukin-23 receptor (IL-23R) antagonistoral peptide immunomodulator
Mechanism of action
Selectively binds the IL-23 receptor and antagonises IL-23 binding, inhibiting IL-23/IL-23R-dependent release of pro-inflammatory cytokines involved in plaque psoriasis pathogenesis.
Indications / reported uses
  • Treatment of moderate-to-severe plaque psoriasis in adults and paediatric patients aged 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy under the US FDA ICOTYDE indication (approved 17 March 2026); the hydrochloride form is a salt of the same active peptide.

Sources: NLM DailyMed — ICOTYDE (icotrokinra) prescribing information · FDA Drug Trials Snapshot — ICOTYDE · MHRA — Icotrokinra approval, 23 October 2026 · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Interleukin-23 receptor (IL-23R) antagonist; oral peptide immunomodulator

Mechanism of action

Selectively binds the IL-23 receptor and antagonises IL-23 binding, inhibiting IL-23/IL-23R-dependent release of pro-inflammatory cytokines involved in plaque psoriasis pathogenesis.

General use cases

  • Treatment of moderate-to-severe plaque psoriasis in adults and paediatric patients aged 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy under the US FDA ICOTYDE indication (approved 17 March 2026); the hydrochloride form is a salt of the same active peptide.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Icotrokinra PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Icotrokinra Permitted Daily Exposure (PDE) report (the Icotrokinra PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Icotrokinra Occupational Exposure Limit (OEL) report (the Icotrokinra OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.